Ovarian Cancer Market Summary
The Ovarian Cancer market size in the 7MM was estimated at USD 3,012 million in 2025 and is expected to reach USD 5,703 million by 2034, growing at a CAGR of approximately 7.40% during the forecast period across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. The United States represents the largest market for ovarian cancer among the 7MM.
Platinum-based chemotherapy has remained the standard of care for ovarian cancer for the past three decades, though the emergence of platinum resistance in recurrent disease continues to pose a persistent clinical challenge. The market is currently dominated by PARP inhibitors in the maintenance setting, alongside a rapidly expanding role for antibody-drug conjugates (ADCs) and targeted combination regimens in specific molecular subsets.
Explore DelveInsight’s Full Coverage on the Ovarian Cancer Market
Ovarian Cancer Overview
Ovarian cancer has a high mortality rate and ranks as the fifth most common cause of death among females worldwide. Its etiology remains unclear, though factors such as smoking, obesity, and an unhealthy diet may influence risk. A family history of breast and ovarian cancer, along with mutations in the BRCA1 and BRCA2 genes, are among the primary risk factors.
Histopathologically, ovarian cancer is classified into five primary epithelial types: serous, clear cell, endometrioid, mucinous, and un-specified. The disease is further categorized into Type I tumors, typically detected early with a favorable prognosis, and Type II tumors, including high-grade serous ovarian cancer (HGSOC), carcinosarcoma, and undifferentiated carcinoma, which are usually diagnosed at advanced FIGO stages with poorer prognosis.
Ovarian cancer often lacks obvious early symptoms, making detection difficult. Common signs include abdominal bloating, early satiety, frequent urination, pelvic or abdominal pain, digestive issues, menstrual irregularities, fatigue, pain during intercourse, and unexplained weight changes.
Ovarian Cancer Diagnosis and Treatment Algorithm
There is currently no standard, widely accepted screening test for ovarian cancer, which contributes to difficulty in early detection since the disease often does not cause noticeable symptoms until it is advanced. Diagnosis is typically suspected based on symptoms, physical examination, and imaging tests such as ultrasound, CT, or MRI, though a definitive diagnosis requires surgery. Blood tests such as CA-125 can support clinical suspicion but are not conclusive on their own. The primary diagnostic procedure is exploratory laparotomy, during which tissue samples are examined and, if cancer is confirmed, the surgeon performs debulking to remove as much cancerous tissue as possible; a less invasive laparoscopy may be used in some cases.
Treatment involves a combination of surgery, radiation, and systemic therapies. Surgery, including staging and debulking, is the primary approach, with fertility-preserving options available for younger patients in select cases. Radiation therapy is rarely first-line but may be used for disease spread, with techniques like MRI-Linac improving precision. Systemic treatment includes platinum-based chemotherapy (typically carboplatin and paclitaxel), hormone therapy for hormone-sensitive tumors, targeted therapies such as bevacizumab, PARP inhibitors for BRCA-mutated tumors, and newer agents such as ELAHERE and BRAF/MEK inhibitors. A patient’s BRCA or HRD (homologous recombination deficiency) status does not alter initial chemotherapy but influences maintenance therapy selection.
Ovarian Cancer Market Players
Ovarian Cancer companies include:
- AstraZeneca
- AbbVie
- GlaxoSmithKline (GSK)
- Genmab
- pharma& GmbH
- Eli Lilly
- Novartis
- Roche
- Verastem Oncology
- Corcept Therapeutics
- Genelux Corporation
- Mural Oncology
- Daiichi Sankyo
- Merck
- Sutro Biopharma
- Bristol-Myers Squibb
- And Others
Ovarian Cancer Epidemiology
The epidemiology section of the Ovarian Cancer market insight report provides historical and forecasted data on incident cases, segmented by age, type, stage, and biomarker status across the 7MM from 2020 to 2034.
Key Findings:
- In the 7MM, the US accounted for the highest number of incident cases of ovarian cancer, with nearly 37,600 total incident cases reported in 2024
- Among EU4 and the UK, the UK had the highest number of LGSOC cases, followed by Germany, while Spain recorded the lowest
- Incident cases of HRD (gLOH ≥ 16%) were notably higher in HGSOC compared to MAPK-driven (BRAF/KRAS/NRAS/NF1) cases, with MAPK alterations predominating in LGSOC; in the US, HRD cases accounted for nearly 5,160 in 2024
- In LGSOC, the majority of cases present with Stage III disease at diagnosis, with about 70-80% diagnosed at Stage III and roughly 10% at Stage IV; in Japan, early-stage and advanced-stage LGSOC cases were around 30 and 325, respectively, in 2024
Ovarian Cancer Market Outlook
The Ovarian Cancer market is projected to grow from USD 3,012 million in 2025 to USD 5,703 million by 2034, at a CAGR of approximately 7.40%. Growth will be supported by the introduction of next-generation targeted agents, ADCs, and immunotherapy combinations, with leading players including AstraZeneca, AbbVie, Genmab, GSK, Verastem, Daiichi Sankyo, Merck, and Novartis investing heavily in the space. The low-grade serous ovarian cancer (LGSOC) segment is currently led by TAFINLAR + MEKINIST, with Avutometinib + Defactinib having gained FDA approval in May 2025 as the first therapy specifically for KRAS-mutated recurrent LGSOC. ELAHERE has emerged as one of the most rapidly adopted ADCs in the US oncology market, with US sales exceeding USD 470 million in 2024, alongside accelerating commercialization overseas.
Get a Detailed Analysis of the Current and Emerging Ovarian Cancer Therapies
Marketed Ovarian Cancer Drugs
- RUBRACA (rucaparib) – pharma& GmbH
RUBRACA is an oral, small-molecule inhibitor of PARP 1, 2, and 3, approved for the maintenance treatment of adult patients with recurrent epithelial ovarian carcinoma (EOC), fallopian tube carcinoma (FTC), or primary peritoneal cancer (PPC) who are in complete or partial response to platinum-based chemotherapy. It received its first US FDA approval in 2016 for BRCA-mutated advanced ovarian cancer. In November 2023, the European Commission granted marketing authorization for RUBRACA as a first-line maintenance treatment for all women with advanced ovarian cancer responding to first-line platinum-based chemotherapy, regardless of BRCA status.
- ZEJULA (niraparib) – GlaxoSmithKline
Niraparib is an oral, potent, and highly selective PARP1/PARP2 inhibitor that works by inhibiting DNA damage repair and inducing cell death. In March 2017, the US FDA approved ZEJULA for maintenance treatment of adult patients with recurrent EOC, FTC, or PPC responding to platinum-based chemotherapy. In 2020, approval was expanded to maintenance treatment of adult patients with advanced EOC, FTC, or PPC in complete or partial response to first-line platinum-based chemotherapy.
- ELAHERE – AbbVie
ELAHERE is approved for FRα-positive, platinum-resistant EOC, FTC, or PPC patients treated with up to three prior therapies, with US initial approval in 2022. It has shown a rapidly successful launch trajectory, generating more than USD 470 million in US sales in 2024.
- LYNPARZA (olaparib) – AstraZeneca/Merck
LYNPARZA is approved for patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have received three or more prior lines of chemotherapy, with US initial approval in 2014. It remains the most successful PARP inhibitor in the ovarian cancer market.
- KEYTRUDA – Merck
KEYTRUDA is approved for MSI-H or dMMR solid tumors, with US initial approval in 2017.
Emerging Ovarian Cancer Drugs
The ovarian cancer pipeline includes a broad range of late-stage (Phase III and Phase II/III) candidates addressing platinum-resistant and platinum-sensitive disease across multiple biomarker-defined subgroups.
- Avutometinib (VS-6766) + Defactinib (VS-6063) – Verastem Oncology
Avutometinib is an RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF, and CRAF, potentially enabling a more complete and durable antitumor response through maximal RAS pathway inhibition. In May 2025, Verastem Oncology announced FDA approval of AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib) for KRAS-mutated recurrent LGSOC in adults previously treated with systemic therapy, the first and only FDA-approved therapy for this indication.
- Relacorilant – Corcept Therapeutics
Relacorilant is a glucocorticoid receptor (GR) agonist in Phase III development for platinum-resistant ovarian cancer (PROC). In September 2025, Corcept Therapeutics announced FDA acceptance of its NDA for relacorilant, with a PDUFA date of July 11, 2026.
- Raludotatug Deruxtecan (R-DXd) – Daiichi Sankyo and Merck
Raludotatug deruxtecan is an investigational, potential first-in-class CDH6-directed ADC built on Daiichi Sankyo’s DXd ADC technology, comprising a humanized anti-CDH6 antibody linked to a topoisomerase I inhibitor payload. It is being evaluated in the Phase II/III REJOICE-Ovarian01 trial, initiated in April 2024, under a global development and commercialization agreement between Daiichi Sankyo and Merck.
- Rinatabart Sesutecan (Rina-S) – ProfoundBio/Genmab
Rinatabart sesutecan is a FRα-targeting ADC in Phase III development for platinum-resistant and platinum-sensitive ovarian cancer.
- Olvimulogene Nanivacirepvec (Olvi-Vec) – Genelux Corporation
Olvi-Vec is an oncolytic therapy administered intraperitoneally, in Phase III development for platinum-resistant/refractory high-grade serous ovarian cancer.
- Nemvaleukin Alfa (ALKS 4230) – Mural Oncology
Nemvaleukin alfa is an IL-2 agonist administered via IV infusion, in Phase III development for platinum-resistant ovarian cancer.
- Catequentinib (Anlotinib) – Advenchen Laboratories
Catequentinib is an oral RTK inhibitor in Phase III development for platinum-sensitive or platinum-resistant recurrent or metastatic ovarian cancer.
- Luveltamab Tazevibulin (STRO-002) – Sutro Biopharma
Luveltamab tazevibulin is a FRα-targeting ADC administered via IV infusion, in Phase III development for ovarian cancer.
- Sacituzumab Tirumotecan – Merck and Kelun-Biotech
Sacituzumab tirumotecan is a TROP2 inhibitor administered via IV infusion, in Phase III development for platinum-sensitive recurrent ovarian cancer.
- Azenosertib (ZN-c3) + Niraparib – Zentalis Pharmaceuticals and K-Group Beta
Azenosertib is an oral WEE1 protein inhibitor in Phase II development for platinum-resistant ovarian cancer.
- TORL-1-23 – TORL BioTherapeutics
TORL-1-23 is a claudin 6-targeted therapy administered via IV infusion, in Phase II development for women with advanced platinum-resistant epithelial ovarian cancer expressing claudin 6.
Additional emerging candidates under evaluation include oregovomab (OncoQuest Pharmaceuticals/Quest PharmaTech/Canariabio) and other novel agents anticipated to expand the treatment landscape as the population of ovarian cancer patients continues to grow.
Ovarian Cancer Drug Class Analysis
PARP inhibitors remain a cornerstone class in ovarian cancer, commonly used in breast and ovarian cancer and particularly effective in tumors with BRCA-related DNA repair deficiencies. RUBRACA, LYNPARZA, and ZEJULA are the established PARP inhibitors in this class; LYNPARZA and ZEJULA are the two leading agents, with ZEJULA holding a broad FDA label allowing use regardless of biomarker status. However, PARP inhibitor use in recurrent maintenance was withdrawn between 2022 and 2023 from certain segments, including non-BRCA ovarian cancer and monotherapy use from third-line and beyond, reflecting the balance between initial optimism and emerging survival-outcome data. These agents remain a crucial option for BRCA-mutated patients, though their universal use in maintenance therapy is no longer supported.
Download the Ovarian Cancer Market Report for In-Depth Insights on Pipeline and Forecast
Conclusion
The Ovarian Cancer market is set for continued expansion through 2034, driven by rising incident cases, improved diagnostic and genetic testing practices, and an actively evolving therapeutic pipeline. While PARP inhibitors have anchored maintenance therapy for BRCA-mutated disease, recent restrictions on their broader use underscore the need for careful patient selection and have accelerated development of next-generation options. ADCs such as ELAHERE, along with RAF/MEK inhibitor combinations, GR agonists, and CDH6- and FRα-targeted therapies in late-stage development, are poised to reshape treatment across platinum-resistant, platinum-sensitive, and biomarker-defined subgroups. As access to these innovative therapies expands, the Ovarian Cancer market is expected to see substantial transformation, creating new opportunities for stakeholders while addressing the persistent unmet needs in this high-mortality disease.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
